local coverage determination Veracyte Bladder Cancer Test Receives Medicare Coverage The patient must be a candidate for multiple potential treatments with varying levels of intensity or multiple therapies. Medicare Administrative Contractor Palmetto Finalizes Coverage of Molecular Testing for Organ Transplant Rejection Under the policy, covered tests must provide information about active rejection status or cellular or antibody-mediated rejection status. Local Coverage Determinations Roundup: Castle Bio A bi-weekly listing of recent local coverage determinations from Medicare Administrative Contractors. CGS Administrators Aligns Medicare Coverage for CareDx AlloSure Tests The company's AlloSure Kidney test received coverage, along with its AlloSure Heart test when used with the firm's AlloMap test. Clinical Genomics Nabs Medicare Coverage for Colorectal Cancer Test as Novitas Revises LCD Novitas added multiple leukemia biomarkers to its coverage determination, as well as the ThyGeNEXT molecular panel. Nov 6, 2020 Medicare Administrative Contractor CGS Aligns Coverage for Melanoma Risk Stratification Tests Nov 2, 2020 GenomeWeb Index Up 5 Percent in October as Favorable Earnings Reports Bolster Shaky Market Oct 28, 2020 Strata Oncology Receives Medicare Coverage for NGS Test Oct 22, 2020 Local Coverage Determinations Roundup: CareDx, Castle Bio, Decipher Biosciences Oct 12, 2020 Pacific Edge Diagnostics Receives Medicare Coverage for Bladder Cancer Test Oct 8, 2020 Castle Bio Receives Expanded Medicare Coverage for Melanoma Test Oct 5, 2020 Resolution Bio Seeks to Widen Private Payor Coverage Following Lung Cancer Liquid Biopsy Launch Premium Oct 1, 2020 CareDx Shares Spike as AlloSure Heart Transplant Test Garners Final LCD From Palmetto Sep 25, 2020 Palmetto Expands Coverage for Decipher Biosciences Prostate Cancer Test Sep 25, 2020 Natera Cancer Liquid Biopsy Test Coverage to Expand Under New Draft LCD Sep 10, 2020 Two Medicare Contractors Align Coverage for MRD Testing With Palmetto Sep 3, 2020 Natera Receives LCD From Palmetto for Signatera MRD Test in Colorectal Cancer Patients Jul 31, 2020 Medicare to Cover Myriad Genetics' BRACAnalysis for FDA-Approved CDx Indications Jul 15, 2020 Noridian Providing Limited Coverage for MDx Tests as Predictive Classifiers for NSCLC Jul 2, 2020 Surge in Stocks of SARS-CoV-2 Dx Developers Pushes GenomeWeb Index Up 15 Percent in H1 2020 Jul 2, 2020 Noridian Aligns With Palmetto on Single-Gene, Multi-Gene PGx Test Coverage Jul 1, 2020 Invitae Stock Skyrockets in June on ArcherDx Acquisition, Leading GenomeWeb Index Jun 19, 2020 Local Coverage Determinations Roundup: Razor Genomics, Guardant Health Jun 11, 2020 Palmetto Providing Limited Coverage for Single-Gene, Multi-Gene PGx Tests Jun 9, 2020 Myriad Genetics' Breast Cancer Recurrence Test Refused Expanded Coverage in Draft LCDs Load More Breaking News Bruker Posts 34 Percent Jump in Q2 Revenues GenomeWeb Index Gains Slightly in July as Fluidigm, PerkinElmer, Bio-Rad Post Strong Increases Feinstein Institutes for Medical Research Wins $2.9M NIH Grant to Study Polygenic Embryo Screening Top Five Articles on GenomeWeb Last Week: CDC, Bio-Rad, 10x Genomics, PerkinElmer, and More InterVenn Biosciences Closes $201M Series C Round Abcam to Acquire Life Science Research Tool Firm BioVision for $340M The Scan And Back The New York Times reports that missing SARS-CoV-2 genome sequences are back in a different database. Lacks Family Hires Attorney A lawyer for the family of Henrietta Lacks plans to seek compensation from pharmaceutical companies that have used her cancer cells in product development, the Baltimore Sun reports. For the Unknown The Associated Press reports that family members are calling on the US military to use new DNA analysis techniques to identify unknown sailors and Marines who were on the USS Arizona. PLOS Papers on Congenital Heart Disease, COVID-19 Infection Host MicroRNAs, Multiple Malformation Mutations In PLOS this week: new genes linked to congenital heart disease, microRNAs with altered expression in COVID-19, and more.